AI in Healthcare India 2026:
What Is Actually Deployed
Published market estimates diverge by ~100×. This analysis maps what is verifiably deployed — radiology, screening, cardiac triage, GenAI operations — the vendor landscape, capital flows, and where AI spend actually moves a hospital P&L.
3 of 12
AI use-case families verifiably deployed at scale
~100×
Divergence in published market-size estimates
US$ 180–220M
Disclosed funding to Indian healthcare AI firms in 2024–25
20–40%
Radiologist time saved per scan in controlled deployments
Why Market-Size Estimates Diverge 100×
The range of published estimates for AI in Indian healthcare — from under US$ 1 billion to over US$ 100 billion — is not a measurement problem. It is a definition problem.
Estimates that reach US$ 50–100 billion include the total addressable opportunity across every healthcare sub-sector where AI could theoretically be applied. Estimates that stay below US$ 2 billion count actual software licences, deployment contracts, and recurring SaaS revenue from AI-specific tools in active use.
InsightRx maps the latter — what is verifiably deployed, contracted, and generating recurring revenue in Indian healthcare today. The addressable opportunity is real. Conflating it with current spend produces projections that are useless for procurement decisions, investment theses, or vendor diligence.
The Three Families That Are Real
Of twelve AI use-case families evaluated, three have crossed from pilot to verifiable deployment at scale in Indian healthcare.
Radiology AI
Tele-reporting, auto-prioritisation of critical findings, and chest X-ray screening are in active use at major diagnostics chains. Qure.ai, Artelus, and in-house tools at Dr. Lal PathLabs and Metropolis are the primary deployment vehicles.
Cardiac Triage AI
ECG interpretation tools from Qure.ai and SigTuple are deployed in emergency and primary care settings. Automated STEMI flagging is the most mature use case.
GenAI for Clinical Operations
Discharge summary generation, ICD coding assistance, and prior authorisation drafting are in active use at Apollo Hospitals, Manipal, and several mid-size chains. This is the fastest-growing deployment category in 2025–26.
The Nine That Are Not (Yet)
These use-case families remain at pilot stage or are vendor claims without verifiable deployment evidence at scale in India as of August 2026.
Full methodology and evidence base in the downloadable report.
A Fragmented Landscape — No Player Holds More Than ~5%
The Indian healthcare AI vendor landscape divides into four categories. No single vendor holds more than approximately 5% of the verifiable deployment base. The market is pre-consolidation.
Domestic AI-first
Qure.ai, Niramai, SigTuple, Artelus
Global platform vendors
Microsoft, Google, AWS — India deployments
Hospital-chain in-house
Apollo Hospitals, Manipal Health Enterprises
Diagnostics-chain proprietary
Dr. Lal PathLabs, Metropolis Healthcare
Capital Flows
US$ 180–220M Deployed in 2024–25
Indian healthcare AI companies raised approximately US$ 180–220 million in disclosed funding in 2024–25. Qure.ai leads with cumulative funding exceeding US$ 100 million.
The funding landscape is bifurcating: well-capitalised AI-first companies with international deployments are attracting growth rounds; early-stage companies without a clear deployment record are finding the environment significantly tighter than 2021–22.
Hospital chains are increasingly building in-house AI capability rather than licensing external tools — a pattern that will compress the addressable market for pure-play AI vendors.
The Four-Question Test for Any AI Purchase
AI spend moves a hospital P&L primarily through radiology throughput and revenue-cycle efficiency. Before any AI purchase, answer these four questions. If you cannot, the purchase is a cost, not an investment.
Name the line
Which specific P&L line does this AI purchase improve — radiology labour cost, claim rejection rate, length of stay?
Name the baseline
What is the current measured value of that line? If you cannot state it, the ROI calculation is fiction.
Name the owner
Who in the organisation is accountable for delivering the improvement? Without a named owner, the result will not be tracked.
Name the review date
When will you measure whether the improvement materialised? A purchase without a review date is a donation.
Want us to run this test against your actual proposals? InsightRx runs the four-question P&L discipline test against live AI purchase proposals for hospitals and health systems. Commission an AI Spend Audit →
Five-Point AI Vendor Diligence Checklist
For investors evaluating a healthcare AI asset. These five checks separate vendors with a real deployment record from those with a compelling deck.
Deployment evidence
Ask for a list of live deployments — not pilots, not POCs. Request reference contacts at two named hospitals or chains.
Customer concentration
What share of revenue comes from the top 3 customers? Concentration above 50% is a risk flag for a vendor claiming scale.
Regulatory moat
Does the product have CDSCO approval for its claimed indication? For diagnostic AI, this is non-negotiable for hospital procurement.
Integration depth
Is the tool a standalone app or integrated into the hospital HIS/RIS/LIS? Standalone tools have high abandonment rates after the pilot.
Outcome data
Can the vendor produce peer-reviewed or independently audited outcome data from Indian deployments — not international studies?
Diligencing a healthcare AI asset? InsightRx provides deployment verification, customer-concentration assessment, and regulatory-moat analysis for investors evaluating AI vendors in Indian healthcare. Commission a Diligence Study →
Common Questions on AI in Indian Healthcare
What AI is actually deployed in Indian healthcare in 2026?
Three use-case families are verifiably deployed at scale: radiology AI (tele-reporting, auto-prioritisation, chest X-ray screening), cardiac triage AI (ECG interpretation), and GenAI for clinical operations (discharge summaries, ICD coding, prior authorisation). The remaining nine use-case families evaluated by InsightRx remain at pilot stage or are vendor claims without verifiable deployment evidence.
Why do AI in healthcare India market size estimates vary so much?
Estimates diverge by approximately 100x because they use different definitions. Estimates of US$ 50–100 billion include the total addressable opportunity across all healthcare sub-sectors where AI could theoretically be applied. Estimates below US$ 2 billion count actual software licences, deployment contracts, and recurring SaaS revenue from AI tools in active use. The InsightRx report maps actual deployment, not addressable opportunity.
Which AI companies are deployed in Indian hospitals?
The leading domestic AI-first companies with verifiable hospital deployments include Qure.ai (radiology, TB screening), SigTuple (haematology, ECG), Niramai (breast cancer screening), and Artelus (diabetic retinopathy). Global platform vendors including Microsoft, Google, and AWS have deployments at major hospital chains. Apollo Hospitals and Manipal have significant in-house AI development programmes.
How does AI spending affect a hospital P&L in India?
Current P&L impact is concentrated in radiology throughput (AI-assisted reporting reduces radiologist time per scan by 20–40%, enabling higher volumes without proportional headcount growth) and revenue-cycle efficiency (GenAI tools for coding and prior authorisation reduce claim rejection rates). Clinical outcome improvements are documented internationally but not yet measurable at scale in Indian deployments.
What is the market size for AI in Indian healthcare?
Published estimates range from under US$ 1 billion to over US$ 100 billion — a ~100x divergence explained entirely by definition. Actual recurring AI software revenue in Indian healthcare (licences, SaaS, deployment contracts) is estimated below US$ 2 billion in 2025–26. The addressable opportunity across all healthcare sub-sectors is much larger but conflating it with current spend produces meaningless projections.
What is the P&L discipline test for AI purchases in healthcare?
InsightRx's four-question test: (1) Name the P&L line the AI purchase improves. (2) Name the current baseline value of that line. (3) Name the person accountable for delivering the improvement. (4) Name the date you will review whether the improvement materialised. Any AI purchase that cannot answer all four questions is not an investment — it is a cost.
Commission a Study
Commission AI-Specific Healthcare Research
InsightRx conducts primary research on AI adoption in Indian healthcare — deployment verification, vendor assessment, P&L impact analysis, and investor diligence. Tell us your question.